LJC 11,036 is the active metabolite of L-084, a novel oral carbapenem that exhibits potent broad-spectrum activity. Antibacterial activities of LJC 11,036 against clinical isolates from respiratory infections, such as Streptococcus pneumoniae (n ‫؍‬ 52), Streptococcus pyogenes (n ‫؍‬ 19), Haemophilus influenzae (n ‫؍‬ 50), Klebsiella pneumoniae (n ‫؍‬ 53), and Moraxella catarrhalis (n ‫؍‬ 53), and from urinary-tract infections, such as Escherichia coli (n ‫؍‬ 53) (MICs at which 90% of the isolates were inhibited [MIC 90 s], 0.1, <0.006, 0.39, 0.05, 0.05, and 0.05 g/ml, respectively), were 2-to 64-fold higher than those of imipenem, cefdinir, and faropenem. Moreover, against these bacterial species, except for H. influenzae, the MIC 90 s of LJC 11,036 were 4-to 512-fold lower than those of levofloxacin. LJC 11,036 showed bactericidal activity equal or superior to that of imipenem. Bactericidal activity against penicillin-resistant S. pneumoniae (PRSP) did not vary with the phase of growth. LJC 11,036 had potent activity against various ␤-lactamase-producing strains, excluding carbapenemase producers. Against renal dehydropeptidase-I, LJC 11,036 was more stable than imipenem. Furthermore, LJC 11,036 produced in vitro postantibiotic sub-MIC effects against PRSP HSC-3 (6.0 h at one-fourth the MIC) and H. influenzae LJ5 (9
not active in vitro, and all studies were performed with LJC 11,036, the active metabolite. Imipenem (Banyu Pharmaceutical Co., Ltd.), faropenem (Yamanouchi Pharmaceutical Co., Ltd./Suntory Ltd.), cefdinir (Fujisawa Pharmaceutical Co., Ltd.), and levofloxacin (Daiichi Pharmaceutical Co., Ltd.) were obtained commercially.
Organisms. Twenty-six aerobic standard strains and 37 ␤-lactamase-producing strains were obtained from the stock culture collection of the Medical Research Laboratories, Lederle (Japan), Ltd. A total of 652 clinical isolates collected between 1994 and 1998 from patients at various hospitals in Japan were used for MIC determinations.
Determination of MICs. MICs were determined by the agar dilution method (10) with Sensitivity Disk Agar-N (SDA; Nissui). SDA supplemented with 5% horse blood was used for streptococci and Moraxella catarrhalis, while SDA supplemented with 5% Fildes enrichment was used for Haemophilus influenzae. One loopful (5 l) of an inoculum corresponding to 10 4 CFU per spot was inoculated on drug-containing agar plates, and the plates were incubated for 18 h at 37°C. The MIC was defined as the lowest drug concentration which inhibited visible growth of bacteria. To examine the effects of different inoculum sizes (10 6 to 10 8 CFU/ml) on the antibacterial activity of LJC 11,036, MIC tests were also performed by the agar dilution method using SDA. The stabilities of LJC 11,036 to ␤-lactamases were determined by drug susceptibility by using the agar dilution method against ␤-lactamase-producing strains.
Determination of MBCs. MICs were determined by the broth dilution method using serial twofold dilutions. Strains were grown overnight in sensitivity test broth (STB; Nissui). Overnight cultures were diluted in fresh STB to approximately 10 6 CFU/ml and inoculated into STB containing various concentrations of each drug. For H. influenzae, STB supplemented with 5% Fildes enrichment was used, while STB supplemented with 5% horse serum was used for Streptococcus pneumoniae. Five microliters of cultures used for the determination of MICs from test tubes showing no visible growth of bacteria were inoculated on SDA plates. The MBC was defined as the lowest drug concentration which inhibited visible growth of bacteria. Drug susceptibility in various phases of growth. Growth curves obtained by monitoring the batch culture in the presence of drugs were examined. The period between the logarithmic and stationary phases was divided into three growth periods, and at each phase drugs were added. Viable counts were determined at the times indicated in Fig. 2 .
In vitro postantibiotic sub-MIC effect. STB supplemented with 5% horse serum was used as the growth medium for penicillin-resistant S. pneumoniae (PRSP) HSC-3. Bacteria in the logarithmic phase of growth (approximately 10 8 CFU/ml) were exposed to the MIC of the test drug at 37°C for 2 h. The drug was removed by a 10 Ϫ2 dilution into fresh medium containing different sub-MIC concentrations (1/16, 1/8, and 1/4 the MIC). Viable counts were determined at 0, 2, 4, 6, and 8 h after the addition of sub-MIC concentrations of drugs. The in vitro postantibiotic sub-MIC effect was calculated according to the method of Licata et al. (7) . For H. influenzae LJ5, STB supplemented with 5% Fildes enrichment was used. After exposure to the drug at twice the MIC for 2 h, the drug was removed by the dilution method. Sub-MIC concentrations of oneeighth, one-fourth, and one-half the MIC were used. Viable counts were determined at 0, 2, 4, 6, 8, 10, and 12 h.
Stability to DHP-I. The stability of LJC 11,036 to renal DHP-I was compared with that of imipenem by using recombinant human DHP-I (9) . Test compounds at a final concentration of 3 mM were incubated at 30°C with DHP-I (enzyme activity, 0.6 U/ml) in 50 mM 3-(N-morpholino)propanesulfonic acid buffer (pH 7.0). After various times of incubation, the concentrations of the compounds were determined by high-performance liquid chromatography (9) .
Binding assays for PBPs. Binding of LJC 11,036 to PBPs of PRSP HSC-3 and H. influenzae LJ5 was determined by previously described competition assays (2, 15) . Solubilized membrane fractions were preincubated for 10 min at 30°C with a nonradioactive compound diluted to various concentrations and then postincubated with [ 3 H]benzylpenicillin for another 10 min at 30°C. PBPs were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and fluorography.
RESULTS
Activity against clinical isolates. (MSSA), methicillin-resistant S. aureus (MRSA) (MIC of methicillin, Ն12.5 g/ml), and Staphylococcus epidermidis were 0.025, 12.5, and 6.25 g/ml, respectively. The activity against MSSA (MIC 90 ) was equal to that of imipenem and 8-to 16-fold higher than those of faropenem, cefdinir, and levofloxacin. LJC 11,036 showed the highest activity against MRSA and S. epidermidis among the drugs tested. MIC 90 s for penicillin-susceptible S. pneumoniae (PSSP), PRSP, and Streptococcus pyogenes were Յ0.006, 0.1, and Յ0.006 g/ml, respectively. Of the compounds used in this study, LJC 11,036 was the most active against streptococci. The in vitro activity of LJC 11,036 against gram-negative bacteria is shown in Table 2 . Against Escherichia coli, Klebsiella pneumoniae, and M. catarrhalis, the MIC 90 s of this compound were 0.05 g/ml; thus, it was 2-to 512-fold more active than the other drugs tested. Against H. influenzae, the activity of LJC 11,036 (MIC 90 s, 0.39 g/ml) was four-to eightfold greater than those of the other ␤-lactams tested, but it was less active than levofloxacin. The MIC 90 s of LJC 11,036 against Enterobacter cloacae (0.2 g/ml) and Proteus mirabilis (0.39 g/ml) were 4-to 64-fold lower than those of imipenem and faropenem. LJC 11,036 was moderately active against Serratia marcescens (MIC 50 , 0.39 g/ml; MIC 90 , 25 g/ml). The activity of LJC 11,036 against Pseudomonas aeruginosa (MIC 50 , 6.25 g/ml; MIC 90 , 100 g/ml) was lower than those of imipenem and levofloxacin but greater than those of faropenem and cefdinir.
Influence of the inoculum size on the MIC. Increasing the inoculum size from 10 6 to 10 8 CFU/ml had little or no significant effect on the in vitro activities of LJC 11,036 or imipenem (Table 3 ). However, the activity of imipenem against extended-spectrum ␤-lactamase (ESBL)-producing K. pneumoniae (TOHO-1 type) was more affected by the inoculum size than that of LJC 11,036. Activity against ␤-lactamase-producing strains. The comparative activities of LJC 11,036 and the other drugs against various ␤-lactamase-producing strains are shown in Table 4 . The MICs of LJC 11,036, imipenem, faropenem, and cefdinir against strains producing various types of ␤-lactamases, except for carbapenemase and cephalosporinase of P. aeruginosa, were Յ0.78, Յ6.25, Յ25, and 0.1 to Ͼ100 g/ml, respectively, indicating that LJC 11,036 was the most stable among the ␤-lactams tested. However, like imipenem, LJC 11,036 was hydrolyzed by carbapenemase.
Correlation between the MIC and MBC. In five of the eight strains tested, there was no difference between the MIC and the MBC for LJC 11,036 (Table 5) ; among the remaining strains, only a twofold difference was noted. The bactericidal activity of LJC 11,036 was the most potent, followed by those of imipenem and cefdinir, in that order.
Bactericidal activity. A decrease of approximately 2 log 10 units in the viable count was observed with LJC 11,036 against PRSP at the three different phases of growth. In contrast, cefdinir did not exhibit bactericidal activity at any of the growth phases (Fig. 2) .
In vitro postantibiotic sub-MIC effect. LJC 11,036, unlike cefdinir, produced a strong drug concentration-dependent postantibiotic sub-MIC effect in vitro against PRSP HSC-3 (Fig. 3) . Significant postantibiotic effects (Ͼ1 h) were observed at all concentrations tested; 1.6 h at one-eighth the MIC and 6.1 h at one-fourth the MIC. Moreover, as shown in Fig. 4 , against H. influenzae LJ5, significant postantibiotic effects were observed at both one-fourth the MIC (1.7 h) and one-half the MIC (9.2 h).
Stability to DHP-I. After incubation at 30°C for 4 h, the residual amount of LJC 11,036 decreased by only about 11% of the initial amount, while that of imipenem decreased by 50% after only 1 h of incubation.
Binding of PBPs. LJC 11,036 showed strong binding to PBP1A, -1B, -2A/2X, -2B, and -3 of PRSP HSC-3, with 50% inhibitory concentrations (IC 50 ) of 0.12, 0.08, 0.16, 0.05, and 0.01 g/ml, respectively (Fig. 5) . Binding of LJC 11,036 to PBP1B, -2, -3A, and -3B of H. influenzae LJ5 was also high (IC 50 , 0.09, 0.01, 0.12, and 0.10 g/ml, respectively). The MICs of LJC 11,036 against PRSP HSC-3 and H. influenzae LJ5 were 0.025 and 0.1 g/ml, respectively.
DISCUSSION
This study demonstrated that LJC 11,036 possesses greater activities than imipenem, faropenem, and cefdinir against the main causative organisms of respiratory and urinary-tract infections, i.e., S. pneumoniae, S. pyogenes, H. influenzae, K. pneumoniae, M. catarrhalis, and E. coli. S. pneumoniae is well known to be a major causative agent of community-acquired pneumonia, bacteremia, meningitis, and acute otitis media. At present the prevalence of PRSP is increasing worldwide, which complicates treatment of these in -FIG. 2 . Influence of the growth phase of PRSP HSC-3 on its susceptibility to LJC 11,036. The MIC of LJC 11,036 is 0.025 g/ml, and that of cefdinir is 1.56 g/ml. 3 . In vitro postantibiotic sub-MIC effect (PAE) of LJC 11,036 against PRSP HSC-3. Bacteria were exposed to the MIC from 0 to 2 h and then diluted into fresh medium containing one-fourth or one-eighth the MIC. Solid circles at 2 h represent the count of viable bacteria after exposure to the MIC, before (higher) and after (lower) 10 Ϫ2 dilution. Open circles, control (no drug).
FIG. 4.
In vitro postantibiotic sub-MIC effect (PAE) of LJC 11,036 against H. influenzae LJ5. Procedures and symbols are as explained for Fig. 3 , except that bacteria were exposed to twice the MIC from 0 to 2 h. drug resistance in PRSP is considered to be due both to multiple changes in PBP1A and PBP2B and to the appearance of PBP2X. However, in strain HSC-3, used in this study, separation of PBP2A and PBP2X could not be detected. As was pointed out by Hakenbeck et al. (6) , this finding may be due to the lot of polyacrylamide used for the preparation of SDS-PAGE.
It is of considerable interest that LJC 11,036 shows high binding affinities for five PBPs, including 2B, which exhibits reduced affinity for oral cephalosporins (16) . For LJC 11,036, the first target PBP of H. influenzae is PBP2, as has been noted with imipenem. The morphological change (induction of a spherical form) associated with PBP2 was observed (data not shown). The stability of LJC 11,036 to various ␤-lactamases, excluding carbapenemases, was demonstrated indirectly by way of determination of the MICs against ␤-lactamase-producing strains. Although LJC 11,036 was less active against P. aeruginosa than imipenem and levofloxacin, this compound exhibits strong binding to PBPs in P. aeruginosa (data not shown). Therefore, the decreased activity against P. aeruginosa may be due to poor permeation through the outer membrane. According to the results of a Phase Ia clinical study (single oral doses of 25 to 200 mg), L-084 showed a high urinary recovery rate (approximately 60 to 70%). Moreover, antibiotic-related diarrhea was not observed with any doses of L-084 (unpublished data). It is considered that the high stability of LJC 11,036 to renal DHP-I contributes to the high urinary recovery. These findings may lead to the efficacious use of L-084 against complicated urinary-tract infections caused by P. aeruginosa.
In conclusion, the specific features of L-084 discussed above warrant further investigation for its potential human clinical application. L-084 may have a potential role in the oral treatment of infections that are less responsive to the currently available oral agents, especially ␤-lactams.
